The Emerging Science of Prophylactic Therapies for Migraine– Patients with frequent migraines and/or who experience functional disability need preventative migraine treatment. However, studies have shown that of the 38% of patients who stand to benefit from prophylactic therapy, only 3-13% of them actually receive it. Calcitonin gene-related peptide (CGRP) monoclonal antibodies are under clinical investigation and constitute a new prophylactic migraine therapy class. Increased physician attention when individualizing treatment plans to maximize therapy efficacy and minimize side effects as well as managing headache triggers and existing comorbidities continue to be vital strategies as new agents emerge and when maximizing patient function.
Illustrate how to factor multiple patient-specific characteristics into the treatment plan when managing migraines.
Examine and discuss the emerging science associated with calcitonin gene related peptide (CGRP) monoclonal antibodies (mAbs) and their role in migraine prevention.
Highlight strategies and tools to assess the impact of migraine on daily functioning and quality of life in order to generate a more personalized and inclusive treatment plan.
1.0 Free AMA Pra CAT 1 CME for Physicians